TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00642447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: helium:oxygen mixture
Study: NCT01093391

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DRUG ELUTING STENT
Description: Site preparation and percutaneous access should be performed as per standard hospital procedures.It is recommended to cross the target lesion with 0.014-inch exchange-length guide wire. The involved lesion should be predilated with appropriately sized balloons using standard techniques. It is strongly encouraged that the Investigators use similar materials and techniques throughout the study to maintain consistency and standardization of care.A stent consists of an endovascular prosthesis with a metallic mesh structure that is implanted at the site of the artery blockage via catheterization procedure. The objective of stenting is to obtain an angiographic appearance of the expanded stent only outside the limits of the target vessel filled with contrast medium.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: BARE METAL STENT
Description: Site preparation and percutaneous access should be performed as per standard hospital procedures.It is recommended to cross the target lesion with 0.014-inch exchange-length guide wire. The involved lesion should be predilated with appropriately sized balloons using standard techniques. It is strongly encouraged that the Investigators use similar materials and techniques throughout the study to maintain consistency and standardization of care.A stent consists of an endovascular prosthesis with a metallic mesh structure that is implanted at the site of the artery blockage via catheterization procedure. The objective of stenting is to obtain an angiographic appearance of the expanded stent only outside the limits of the target vessel filled with contrast medium.
Study: NCT01505439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: solifenacin
Description: oral
Study: NCT02854748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25mg
Description: Empagliflozin 25 mg QD for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25mg
Description: Empagliflozin 25 mg QD for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25mg
Description: Empagliflozin 25 mg QD for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25mg
Description: Empagliflozin 25 mg QD for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25mg
Description: Empagliflozin 25 mg QD for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25mg
Description: Empagliflozin 25 mg QD for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lobeglitazone 0.5mg
Description: Lobeglitazone 0.5mg QD for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lobeglitazone 0.5mg
Description: Lobeglitazone 0.5mg QD for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lobeglitazone 0.5mg
Description: Lobeglitazone 0.5mg QD for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lobeglitazone 0.5mg
Description: Lobeglitazone 0.5mg QD for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lobeglitazone 0.5mg
Description: Lobeglitazone 0.5mg QD for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lobeglitazone 0.5mg
Description: Lobeglitazone 0.5mg QD for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25mg/Lobeglitazone 0.5mg
Description: Empagliflozin 25 mg + Lobeglitazone 0.5mg QD for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25mg/Lobeglitazone 0.5mg
Description: Empagliflozin 25 mg + Lobeglitazone 0.5mg QD for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25mg/Lobeglitazone 0.5mg
Description: Empagliflozin 25 mg + Lobeglitazone 0.5mg QD for 5 days
Study: NCT02961283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASN003 MTD
Description: The highest safe and well tolerated dose selected from the doses tested in Part A of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASN003 MTD
Description: The highest safe and well tolerated dose selected from the doses tested in Part A of the study.
Study: NCT03073122

Intervention type: DIAGNOSTIC_TEST
Intervention: Brain MRI, neurocognitive and psychological testing
Description: MRI of the brain and multiple tests of neurocognitive and psychological function including executive function, anxiety and depression
Study: NCT04198376

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group A The Laterally Closed Tunnel Technique with SCTG
Description: Following the administration of local anaesthesia 2% lignocaine hydrochloride.In the LCT technique a bevelled intrasulcular incisions will be made around the necks of the affected teeth with Orban Knife.The tunnelling will be accomplished with tunneling instrument (TKN2).A mucoperiosteal tunnel will be prepared using a specially designed tunneling instrument.The muscle and collagen fibres will be released using surgical blades and gracey curettes.Subepithelial CTG will be harvested from palate using single incision technique.The graft will be removed and will be placed on saline soaked gauze and kept wet until its transfer to the recipient bed.An immediate closure of the donor site is performed using modified mattress sutures.The graft will be adapted to the CEJ by means of sling suture.Finally the margins of the pouch will be pulled together over the graft and sutured with interrupted sutures.The surgical sites will be protected with a non eugenol periodontal dressing.
Study: NCT04198376

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group B Modified Coronally Advanced Tunnel Technique with SCTG.
Description: In MCAT technique all the buccal tissues will be undermined and connected only the papillary region will be left attached.A full thickness preparation of the papillary region will be created this will be done with a small elevator.A second surgical site to obtain the subepithelial CTG using single incision technique.A support suture will be performed to guide the CTG into the recipient site.The graft will be gently pushed into the pouch with a packing instrument and by pulling the support suture.The entire gingivopapillary complex will be moved coronally using a vertical mattress suture anchored in the lingual gingiva.The anchorage in the lingual gingiva will be placed far apically.The suture must capture the buccal flap and graft to avail optimal stabilization.The surgical sites will be protected with a non eugenol periodontal dressing.
Study: NCT00081900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DENSPM )
Description: Each patient will receive DENSPM at an initial dose of 30mg/m\^2, then escalating to 120mg/m\^2, single IV infusion on D1,3,5,8,10,12 of every 28 days as one cycle, planned for 8 cycles if no withdrawn occur
Study: NCT03145584

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Bupivacaine via Adductor Canal Saphenous Catheter
Description: 12.5 mg/hr of bupivacaine was administered continuously via a paraneural catheter for 48 hours following surgery to determine whether superior analgesia was obtained when compared to single shot block with a sham catheter.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Single Shot Adductor Canal Saphenous Block with Bupivacaine
Description: A sham catheter was placed on the skin and covered in a dressing to blind the patient, data collector and investigator as to group allocation
Study: NCT00735839

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V710
Description: V710 vaccination (60 mcg, 0.5 ml) single injection on Day 1

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline placebo (0.5 ml) single injection on Day 1
Study: NCT02665039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinflunine
Description: Vinflunine will be given intravenously once every 21 days, starting at a dose of:~* 280 mg/m2 in patients with GFR 40-60 ml/min~* 250 mg/m2 in patients aged \>80 years and/or GFR 30-40 ml/min

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine will be given intravenously on day 1 and day 8 of every 21 day cycle, starting at a dose of 1000 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine will be given intravenously on day 1 and day 8 of every 21 day cycle, starting at a dose of 1000 mg/m2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin will be given intravenously once every 21 days, starting at a dose of AUC 4.5
Study: NCT00346398

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oral mucosal immunoprophylaxis (OMIP)
Description: OMIP consists of a mixture of allergen extracts including 0.2 milliliters (mL) timothy grass, 0.2 mL cat, and 0.2 mL house dust mite for a total daily dose of 0.6 mL.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo consists of three 0.2 mL vials of solution mixed together for a total daily dose of 0.6 mL.
Study: NCT00848094

Intervention type: RADIATION
Group type: OTHER
Intervention: 3DCRT/IMRT
Description: The starting radiation doses were the total tumor doses of 46 Gy in 2 Gy per fractions for arm I . Escalation was achieved by increasing the tumor dose of each cohort in increments of 4.0 Gy. Subsequent cohorts received higher doses up to a chosen maximum of 62 Gy for arm I.

Intervention type: RADIATION
Group type: OTHER
Intervention: 3DCRT/IMRT
Description: The starting radiation doses were the total tumor doses of 40 Gy in 2 Gy per fractions for arm II. Escalation was achieved by increasing the tumor dose of each cohort in increments of 4.0 Gy. Subsequent cohorts received higher doses up to a chosen maximum of 52 Gy for arm II.
Study: NCT03008785

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: The training program consisted of aerobic and resisted combined physical exercises performed during 10 weeks, three times weekly with 45 minutes sessions: 5 minutes of warm-up on treadmill, 20 minutes of aerobic exercises and 20 minutes of resistance exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: The training program consisted of aerobic and resisted combined physical exercises performed during 10 weeks, three times weekly with 45 minutes sessions: 5 minutes of warm-up on treadmill, 20 minutes of aerobic exercises and 20 minutes of resistance exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: isoflavone
Description: Daily supplementation in 1 capsule per day of 100mg of isoflavones (containing 3.3% genistein, 93.5% dadzein and 3.2% glycitein).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Daily supplementation in 1 capsule per day containing starch of corn.
Study: NCT01709630

Intervention type: DRUG
Intervention: Magnesium sulfate infusion
Description: Participants will be given magnesium sulfate infusion as part of their normal care for either preeclampsia, tocolysis, or neuroprotection.

Intervention type: DRUG
Intervention: Magnesium sulfate infusion
Description: Participants will be given magnesium sulfate infusion as part of their normal care for either preeclampsia, tocolysis, or neuroprotection.
Study: NCT05125549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Сlopidogrel bisulfate film-coated tablets, 75 mg (JSC Farmak, Ukraine)
Description: One film-coated tablet was administrated orally with 240 ml of water after an overnight fast

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Plavix® 75 mg film-coated tablets (Sanofi Winthrop Industrie, France)
Description: One film-coated tablet was administrated orally with 240 ml of water after an overnight fast
Study: NCT00709787

Intervention type: OTHER
Intervention: Usual Care
Description: Normal care for hypertensive patients with risk factors for CHD
Study: NCT02111499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAS41004-IMP1
Description: daily topical application

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAS41004-IMP1
Description: daily topical application
Study: NCT02854748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25mg/Lobeglitazone 0.5mg
Description: Empagliflozin 25 mg + Lobeglitazone 0.5mg QD for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25mg/Lobeglitazone 0.5mg
Description: Empagliflozin 25 mg + Lobeglitazone 0.5mg QD for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25mg/Lobeglitazone 0.5mg
Description: Empagliflozin 25 mg + Lobeglitazone 0.5mg QD for 5 days
Study: NCT04581551

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SWE assessor 1
Description: SWE for 6 shoulder muscles will be performed.~* m. supraspinatus~* m. infraspinatus~* m. rhomboideus major~* m. deltoideus~* m. pectoralis major~* m. pectoralis minor

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SWE assessor 1
Description: SWE for 6 shoulder muscles will be performed.~* m. supraspinatus~* m. infraspinatus~* m. rhomboideus major~* m. deltoideus~* m. pectoralis major~* m. pectoralis minor

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SWE assessor 2
Description: SWE for 6 shoulder muscles will be performed.~* m. supraspinatus~* m. infraspinatus~* m. rhomboideus major~* m. deltoideus~* m. pectoralis major~* m. pectoralis minor
Study: NCT02111499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAS41004-IMP1
Description: daily topical application
Study: NCT04581551

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stretch intervention
Description: Transversal stretch of pectoralis major muscle on the hemiplegic side.
Study: NCT02111499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAS41004-IMP1
Description: daily topical application

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LAS41004-IMP1
Description: daily topical application

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LAS41004-IMP1
Description: daily topical application

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAS41004 IMP2
Description: daily topical application

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAS41004 IMP2
Description: daily topical application

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAS41004 IMP2
Description: daily topical application

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAS41004 IMP2
Description: daily topical application

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LAS41004 IMP2
Description: daily topical application

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LAS41004 IMP2
Description: daily topical application

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAS41004 IMP3
Description: daily topical application

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAS41004 IMP3
Description: daily topical application
Study: NCT04581551

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No stretch intervention
Description: Passive mobilisation of the hemiplegic hand.
Study: NCT00235716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dl-alpha-tocopherol
Description: Alpha-tocopherol will be given as an oral dose of 1000 IU twice a day (morning and evening). The form of vitamin E that will be used in this study will be hard gel capsules of dl-alpha-tocopheryl acetate (synthetic) vitamin E.
Study: NCT01829542

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Freeze-dried blueberry powder dissolved in water
Description: Wild blueberry freeze-dried powder dissolved in water

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Freeze-dried blueberry powder dissolved in water
Description: Wild blueberry freeze-dried powder dissolved in water

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Freeze-dried blueberry powder dissolved in water
Description: Wild blueberry freeze-dried powder dissolved in water

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Freeze-dried blueberry powder dissolved in water
Description: Wild blueberry freeze-dried powder dissolved in water

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Freeze-dried blueberry powder dissolved in water
Description: Wild blueberry freeze-dried powder dissolved in water

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Macro- and micro-nutrient matched control in water
Study: NCT00235716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: A moderate-affinity NMDA antagonist. Memantine will be titrated over four weeks to a maintenance dose of 10 mg twice a day. During week 1 patients will take one 5-mg memantine tablet in the morning. During week 2 patients will take one 5-mg memantine tablet in the morning and one in the evening. During week 3 patients will take two 5-mg memantine tablets in the morning and one 5-mg tablet in the evening. Beginning with week 4, participants will take four 5-mg tablets daily, two in the morning and two in the evening.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dl-alpha-tocopherol
Description: Alpha-tocopherol will be given as an oral dose of 1000 IU twice a day (morning and evening). The form of vitamin E that will be used in this study will be hard gel capsules of dl-alpha-tocopheryl acetate (synthetic) vitamin E.
Study: NCT01072227

Intervention type: PROCEDURE
Intervention: Sample Collection
Description: Tissue
Study: NCT02741336

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Description: Cognitive-behavioral therapy is a short-term, focused psychotherapy for a wide range of psychological and behavioral issues including depression, anxiety, anger, and non-compliance. The focus of the intervention is on how one thinks, behaves, and communicates in real time, as opposed to a focus on one's early childhood experiences. The therapist assists the patient in identifying specific distortions and biases in thinking and provides guidance on how to modify these beliefs. CBT helps the patient learn effective self-help skills that are used in homework assignments that ultimately help change the way one thinks, feels and behaves. The~￼ intervention is action-oriented, practical, rational, and helps the patient gain independence and effectiveness in dealing with real-life issues. Techniques utilized in CBT-I include psychoeducation, sleep hygiene, cognitive restructuring, stimulus control, sleep restriction, and relaxation training.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Monitoring
Study: NCT04918524

Intervention type: DRUG
Intervention: Prednisone
Description: 5-30mg, po, once per day(Qd) prescribed if needed and adjusted due to patient response

Intervention type: DRUG
Intervention: Prednisone
Description: 5-30mg, po, once per day(Qd) prescribed if needed and adjusted due to patient response

Intervention type: DRUG
Intervention: Hydroxychloroquine
Description: 100-200mg, po, twice per day (Bid) prescribed if needed and adjusted due to patient response.

Intervention type: DRUG
Intervention: Hydroxychloroquine
Description: 100-200mg, po, twice per day (Bid) prescribed if needed and adjusted due to patient response.

Intervention type: DRUG
Intervention: Aspirin
Description: 100mg, po, once per day (Qd) prescribed if needed and adjusted due to patient response to 32 weeks of pregnancy. 75mg po, once per day (Qd) to 34 weeks of pregnancy. 50mg po, once per day (Qd) to 36 weeks of pregnancy.

Intervention type: DRUG
Intervention: Aspirin
Description: 100mg, po, once per day (Qd) prescribed if needed and adjusted due to patient response to 32 weeks of pregnancy. 75mg po, once per day (Qd) to 34 weeks of pregnancy. 50mg po, once per day (Qd) to 36 weeks of pregnancy.

Intervention type: DRUG
Intervention: low molecular weight heparin Enoxaparin
Description: 40-60mg, ih, Subcutaneous injection, once per day (Qd) or twice per day (Bid) if needed and adjusted due to patient response.

Intervention type: DRUG
Intervention: low molecular weight heparin Enoxaparin
Description: 40-60mg, ih, Subcutaneous injection, once per day (Qd) or twice per day (Bid) if needed and adjusted due to patient response.
Study: NCT04470960

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training course for the community center health coordinators
Description: These community centers who have volunteered to join the project will receive a 12 week training session which includes the values and principles of health promotion and the principles of building a health promotion project.~The participants will be requested to build a health promotion project within their community. Building and implementing the project will be assisted by a health promotion specialist. Each health promotion project will be evaluated according to the principles of health promotion.
Study: NCT01537458

Intervention type: PROCEDURE
Intervention: follow-up of isolated tricuspid valve repair
Description: follow-up of patients that underwent TV repair in the past.
Study: NCT01371721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DVS SR
Description: Subjects will receive a flexible-dose of 20, 25, 35 or 50 mg/day as prescribed by the investigator.
Study: NCT00556283

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: STARR
Description: Stapled Trans-Anal Rectal Resection for the treatment of ODS

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Biofeedback
Description: electromyographic-based treatment sessions
Study: NCT01747733

Intervention type: DEVICE
Intervention: Bispectral Index
Description: use of BiS-monitor in the assessment of the level of sedation in patients receiving sedation in endoscopy procedures when compared to clinical sedation scales, such as the Richmond agitation-sedation score.
Study: NCT03121625

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous CAR-T
Description: Patients will be drawn 50-100 ml blood to obtain enough peripheral blood mononuclear cells (PBMC) for CAR-T manufacturing. The T cells will be purified from the PBMC, transduced with CAR lentiviral vector, expanded in vitro and then frozen for future administration. Chemotherapy will then be given. Following tumor burden reassessment, CAR-T cells will be infused.
Study: NCT04406324

Intervention type: OTHER
Intervention: No intervention
Description: No Intervention. The study consists in a prospective clinical longitudinal follow-up
Study: NCT00280059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: dose 150-600 mg/day given BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamotrigine
Description: dose 100-500 mg/day given BID